Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
Mycobacterium infections
MeSH D009164 - mycobacterium infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D000193:
Actinomycetales infections
41 Companies
4 Drugs
$
Success rate
D009164:
Mycobacterium infections
51 Companies
15 Drugs
$
Success rate
D009165:
Nontuberculous mycobacterium infections
44 Companies
8 Drugs
$
Success rate
D014376:
Tuberculosis
40 Companies
10 Drugs
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Johnson & Johnson
Bedaquiline
Sirturo
2026-12-01
2012-12-28
Novartis
Clofazimine
Lamprene
1986-12-15
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
0
%
0/0
Phase 2
0
%
0/1
Phase 3
88
%
14/16
Approved:
12
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
Bedaquiline
Novartis
Clofazimine
Sanofi
Isoniazid
,
Pyrazinamide
,
Rifampin
,
Rifapentine
Pfizer
Rifabutin
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use